A new class of antiemetic agents on the horizon.
This article reviews a new class of antiemetic agents, the neurokinin-1 (NK-1) receptor antagonists (RAs). Clinical trials of an NK-1 RA, aprepitant, are ongoing.
Rittenberg
Cynthia N
CN
cindyrit@bellsouth.net
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D064729:Neurokinin-1 Receptor Antagonists